98069-8

SARS-CoV-2 (COVID-19) Ab [Presence] in Saliva (oral fluid) by Rapid immunoassay

Active

Term Description

Qualitative detection of total antibodies against SARS coronavirus 2 (SARS-CoV-2), also known as the 2019 Novel Coronavirus (2019-nCoV), in oral fluid by rapid immunoassay methods. This test detects but does not differentiate between antibody isotypes (IgA, IgG, IgM). Testing is performed for the diagnosis of Coronavirus Disease 2019 (COVID-19).
Source: Regenstrief LOINC

Part Descriptions

LP417540-4   SARS coronavirus 2
The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.

The full genome of the 2019-nCoV was first posted by Chinese health authorities in GenBank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAI) portal. This facilitated detection of the virus globally with subsequent sequences being nearly identical, suggesting a single, recent emergence from a virus related to bat coronaviruses and the SARS coronavirus. Source: LOINC

LP7565-7   Saliva
Saliva is produced primarily by the parotid, submaxillary, and sublingual glands. It is secreted at the rate of 0-3 milliliters per minute which is affected by various factors including anxiety, hydration and hunger. Oral fluid is broadly used to test for drugs of abuse in employment and forensic settings, and is especially useful since it is difficult to adulterate, is quick and is non-invasive. Oral fluid is used to test a variety of analytes, including to test alcohol, HIV and other antibodies, therapeutic drugs and steroids, but its primary use is to test for drugs of abuse including amphetamines, cocaine and metabolites, opioids, methadone, cannabis and heroin. PMID: 17268583 Source: Regenstrief LOINC

Reference Information

Fully-Specified Name

Component

SARS coronavirus 2 Ab

Property

PrThr

Time

Pt

System

Saliva

Scale

Ord

Method

IA.rapid

Additional Names

Short Name

SARS-CoV-2 Ab Sal Ql IA.rapid

Display Name

SARS-CoV-2 (COVID-19) Ab IA.rapid Ql (Sal)

Consumer Name Alpha Get Info

SARS-CoV-2 (COVID-19) antibody, Saliva

Example Answer List: LL2021-5

Basic Attributes

Class

MICRO

Type

Laboratory

First Released

Version 2.71

Last Updated

Version 2.72

Order vs. Observation

Both

Member of these Groups Get Info

Language Variants Get Info

Related Names

• 2019 Novel Coronavirus
• 2019-nCoV
• ABS
• Aby
• Antby
• Anti
• Antibodies
• Antibody
• Autoantibodies
• Autoantibody
• Corona virus
• COVID19
• COVID-19
• EIA
• ELFA
• ELISA
• Enzyme immunoassay
• IAA
• ID
• II
• Infectious Disease
• InfectiousDisease
• MEIA
• Microbiology
• Oral fluid
• Ordinal
• PH
• Point in time
• PR
• Public Health
• PublicHealth
• Ql
• Qual
• Qualitative
• Random
• Sal
• SARS Coronavirus 1
• SARS-CoV
• SARS-CoV-1
• SARS-CoV-2
• Screen
• Severe Acute Respiratory Syndrome
• SUDS
• Viral Pneumonias
• Wuhan coronavirus

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=98069-8

Third Party Copyright

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.